SV

Street Verdict

Analyst Scorecard

SUDEEPPHRM · NSE

Sudeep Pharma Limited

₹1,155

+4.49% (+₹49.6)

Prev. close

₹1,105.4

Volume

2,17,226

Delivery %

56.8%

As of

18 Sept 2026

Price history

₹1,155+₹423.6 (+57.92%) · 3M
10 Jun 2026 → 18 Sept 2026
₹1,344.2₹729.810 Jun03 Jul03 Aug26 Aug18 Sept
Daily closes · updates after each session

No analyst calls on this stock in the last 90 days yet.

Explore by date range →

Analyst opinions

No analyst calls on Sudeep Pharma Limited in the last 90 days.

Fundamentals

About Sudeep Pharma Limited

Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in India, the United States, and internationally. The company provides mineral salts, such as iron, calcium, sodium, zinc, copper, magnesium, manganese, potassium, picolinates, simethicone, and others;It also offers micronutrient premixes and liposomal, encapsulated ingredients, spray-dried formats, granulated ingredients, and triturated for sports nutrition, medical and clinical nutrition, infant nutrition, beverages, fortified staples, functional foods, and dairy products. In addition, the company provides a range of mineral powders and granules for carbonated, non-carbonated, and nutraceutical beverages; tricalcium phosphate, dicalcium phophate, dipotassium phosphate, ferric pyrophosphate, and disodium phosphate. Sudeep Pharma Limited was incorporated in 1989 and is based in Vadodara, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Sujit Jaysukh Bhayani

Headquarters

Vadodara

Employees

525

Key stats

Market cap

₹12,915.68 Cr

P/E ratio (TTM)

70.7

Dividend yield

0.14%

EPS (TTM)

₹16.17

Beta (1Y · daily vs NIFTY 50)

0.89

Shares float

2.54 Cr

EPS · quarter ended Jun 2026

₹3.59

Financial Performance

01 · Financials

0 Cr250 Cr500 Cr750 Cr₹0%10%20%30%FY23FY24FY25FY26
RevenueNet incomeEBITDARevenue growth YoY

FY23 growth needs FY22 filings, which the data source doesn't provide.

02 · Earnings Per Share (EPS)

05101520₹FY23FY24FY25FY26

03 · Dividend Profile

0112₹0%0.1%0.1%0.1%0.2%23 Jul 26
Dividend (₹/share)Annualised yield

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-50%0%50%100%FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr500 Cr1000 Cr1500 Cr₹0×0.25×0.5×0.75×1×FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr500 Cr1000 Cr1500 Cr₹FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-100 Cr0 Cr100 Cr200 Cr₹FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY23FY24FY25FY26
₹426.17 Cr₹454.67 Cr₹497.41 Cr₹642.26 Cr
EBITDA₹97.30 Cr₹186.90 Cr₹198.09 Cr₹250.49 Cr
₹62.32 Cr₹133.19 Cr₹138.73 Cr₹174.29 Cr
Diluted EPS₹5.52₹11.79₹12.28₹15.5

Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.

09 · Balance Sheet

Annual

Line itemFY23FY24FY25FY26
₹420.11 Cr₹513.87 Cr₹717.17 Cr₹1,174.88 Cr
₹83.08 Cr₹78.08 Cr₹137.55 Cr₹150.42 Cr
Stockholders' equity₹223.29 Cr₹356.03 Cr₹493.09 Cr₹883.34 Cr

CWIP, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY23FY24FY25FY26
₹48.40 Cr₹65.69 Cr₹48.73 Cr₹69.55 Cr
Investing cash flow₹-50.02 Cr₹-49.28 Cr₹-78.76 Cr₹-330.93 Cr
₹-9.78 Cr₹-12.74 Cr₹52.70 Cr₹247.29 Cr
Capital expenditure₹-47.15 Cr₹-52.46 Cr₹-64.23 Cr₹-118.15 Cr
End cash position₹10.30 Cr₹13.98 Cr₹36.81 Cr₹26.74 Cr

Dividends paid has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemNov 25–Jun 26(4Q)
Promoter76.15%
Public23.85%
Employee trusts0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.48 L Cr₹1,837.337.05.3613.7%0.06+11.9%+11.4%
Divi's Laboratories Limited₹2.47 L Cr₹9,37583.314.7715.3%0.00+12.3%+53.4%
Torrent Pharmaceuticals Limited₹1.83 L Cr₹4,87576.921.8225.8%1.79+21.5%+37.4%
Apollo Hospitals Enterprise Limited₹1.26 L Cr₹8,944.560.413.3020.5%0.90+15.7%+13.9%
Lenskart Solutions Limited₹1.18 L Cr₹707.2179.913.485.6%0.35+35.4%—
Zydus Lifesciences Limited₹1.13 L Cr₹1,16025.34.1818.6%0.46+18.4%+10.7%
Cipla Limited₹1.10 L Cr₹1,376.332.53.1911.3%0.02+2.1%-11.8%
Laurus Labs Limited₹1.05 L Cr₹1,95496.419.8616.8%0.48+22.0%+111.6%
Max Healthcare Institute Limited₹1.01 L Cr₹1,049.369.89.3913.4%0.32+19.0%-10.6%
Dr. Reddy's Laboratories Limited₹97,876.16 Cr₹1,18529.62.6011.4%0.21+3.2%-10.4%
Manipal Health Enterprises Limited₹97,364.22 Cr₹738.95146.611.567.8%1.53+18.0%—
Sudeep Pharma Limited₹12,915.68 Cr₹1,15570.714.6219.6%0.17+28.4%—

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

IPO documents

Annual reports

Concall transcripts

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

Index membership

10 indices

Nifty IPO· 0.9%BSE IPO· 0.7%BSE Commodities· 0.2%Nifty Smallcap 500· 0.1%BSE 1000· 0.0%Nifty Total Market· 0.0%BSE 250 MICROCAPBSE NEXT 500BSE Smallcap 500Nifty Microcap 250

NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.

SUDEEPPHRM

Sudeep Pharma - Multibagger Stocks: 14 microcaps surged up to 355% in just 6 months

The Economic Times · 10 days ago

SUDEEPPHRM

Sudeep Pharma Share Price Falls 5%: Full Stock Analysis

Univest · 10 days ago